Morphotek, Inc.

The Johns Hopkins University

Eisai Inc.

Other

Vogelstein, Bert

Grasso, Luigi

Sass, Philip, M.

Nicolaides, Nicholas, C.

Kinzler, Kenneth

Philip M Sass

Nicholas C Nicolaides

Luigi Grasso

Wolfgang Ebel

Eric Routhier

Bert Vogelstein

Kenneth W Kinzler

Yuhong Zhou

Tao Sai

Marc Berger

Jian Li

Qimin Chao

Brian Tomkowicz

Nicholas E Nicolaides

Shaohong Liang

Howard Sands

J Bradford Kline

Brian E Tomkowicz

Nicolas C Nicolaides

Nicholas C Nicholaides

Gaurav Deshmukh

This invention relates to novel monoclonal antibodies that specifically bind to the alpha-folate receptor. In some embodiments, the antibodies inhibit a biological activity of folate receptor-&#x3b1; (FR-&#x3b1;). The antibodies are useful in the treatment of certain cancers, particularly cancers that have increased cell surface expression of the alpha-folate receptor ('FR-&#x3b1;'), such as ovarian, breast, renal, colorectal, lung, endometrial, or brain cancer. The invention also relates to cells expressing the monoclonal antibodies, antibody derivatives, such as chimeric and humanized monoclonal antibodies, antibody fragments, and methods of detecting and treating cancer using the antibodies, derivatives, and fragments.

Monoclonal antibodies that specifically block biological activity of a tumor antigen

Provided herein are antibodies that specifically bind and neutralizeenterotoxin B. In addition, nucleic acids encoding such antibodies, and cells that express such antibodies are provided. Also provided are methods for treating diseases mediated by, and for neutralizingenterotoxin B.

High affinity antibodies that neutralizeenterotoxin B

This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing folate receptor alpha (FRA) and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to FRA-expressing cells as well as in eliciting an immune-effector activity particularly on tumor cells and precursors. The invention is also related to nucleotides encoding the antibodies of the invention, cells expressing the antibodies; methods of detecting cancer cells; and methods of treating cancer using the antibodies.

Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells

The invention provides methods for inhibiting the interaction of endosialin with endosialin ligands. The inhibition is effectuated on the genetic level, by inhibiting endosialin gene expression, and on the protein level, by blocking the interaction of cell-surface expressed endosialin with ligands such as fibronectin and collagen. The invention provides methods for identifying inhibitors of the interaction of endosialin with endosialin ligands. Also provided are methods for inhibiting angiogenesis and neovascularization in vivo and in vitro.

Methods for inhibiting the binding of endosialin to ligands

Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease.

Antigenic GM-CSF peptides and antibodies to GM-CSF

[object Object]

This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and become internalized by mesothelin-positive cells and also induce an immune effector activity such as antibody dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to mesothelin expressing cells as well as eliciting an immune-effector activity particularly on tumor cells and precursors. The invention is also related to cells expressing the monoclonal antibodies, polyclonal antibodies, antibody derivatives, such as human, humanized, and chimeric monoclonal antibodies, antibody fragments, mammalian cells expressing the monoclonal antibodies, derivatives and fragments, and methods of treating cancer using the antibodies, derivatives and fragments.

Anti-mesothelin antibodies

Described herein are antibodies that specifically bind ganglioside GD2. Also described are nucleotides encoding such antibodies, cells expressing such antibodies, methods of use for such antibodies, and methods for using the antibodies to treat diseases associated with ganglioside GD2. In addition, tissue culture media supplements are described as are methods of use for the supplements. Described herein are albumin-ganglioside conjugates and corresponding methods for producing such conjugates. Methods of purifying or isolating antibodies are also described.

Cells expressing anti-GD2 antibodies and methods related thereto

Growing community of inventors

Audubon, PA, United States of America

Philip M Sass